Earnings summaries and quarterly performance for INVO.
Research analysts covering INVO.
Recent press releases and 8-K filings for INVO.
INVO Fertility Stockholders Approve Key Proposals at Special Meeting
INVO
Proxy Vote Outcomes
Auditor Change
- INVO Fertility stockholders held a special meeting on January 22, 2026, where all five proposals presented were preliminarily approved.
- Key approvals included the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal year 2025.
- Stockholders approved significant changes to the company's capital structure, including the issuance of up to 4,733,728 shares of Common Stock upon the exercise of a warrant from a private placement, and an increase in authorized shares of Common Stock from 6,250,000 to 250,000,000.
- Additionally, an amendment to the 2019 Stock Incentive Plan was approved, increasing the total shares available for issuance to 1,000,000.
Jan 22, 2026, 5:00 PM
INVO Fertility Stockholders Approve Key Proposals at Special Meeting
INVO
Auditor Change
Proxy Vote Outcomes
Executive Compensation
- INVO Fertility held a special meeting on January 22, 2026, where stockholders preliminarily approved all five proposals presented.
- Stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- The issuance of up to 4,733,728 shares of Common Stock upon the exercise of a Warrant from a Private Placement transaction that closed on December 4, 2025, was approved.
- An amendment to increase the number of authorized shares of Common Stock from 6,250,000 to 250,000,000 was approved.
- An increase in the number of shares available for issuance under the 2019 Stock Incentive Plan was approved, with the documents stating the total amount as either 1,000,000 or 1,000,000,000.
Jan 22, 2026, 5:00 PM
INVO Fertility Stockholders Preliminarily Approve Key Proposals for Strategic Growth
INVO
Proxy Vote Outcomes
Auditor Change
New Projects/Investments
- At a special meeting on January 22nd, 2026, INVO Fertility stockholders preliminarily approved the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal year 2025.
- Stockholders also preliminarily approved the issuance of up to 4,733,728 shares of Common Stock upon the exercise of a Warrant from a private placement that closed on December 4th, 2025.
- A significant amendment to the Articles of Incorporation was preliminarily approved, increasing the authorized shares of Common Stock from 6,250,000 to 250,000,000.
- The Fourth Amendment and restatement of the 2019 Stock Incentive Plan was preliminarily approved, increasing shares available for issuance to 1,000,000.
- CEO Steve Shum stated that the meeting's outcome was a critical step to executing the company's strategic growth plan for the year.
Jan 22, 2026, 5:00 PM
INVO Bioscience Discusses Growth Strategy and Market Outlook
INVO
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- INVO Bioscience currently operates three fully operational fertility clinics and has signed a purchase agreement to acquire a practice in Indianapolis.
- The company's growth strategy for the near and intermediate term focuses on acquisitions, with a robust pipeline of potential opportunities, alongside organic expansion within existing clinics through increased patient flow and new service offerings.
- INVO aims to address the $5-$7 billion U.S. fertility market by providing more efficient and affordable care, leveraging both its clinic operations and the FDA-cleared INVOcell device.
- For 2026, INVO anticipates exciting growth driven by both organic efforts and strategic acquisitions, expecting to exit the year in its strongest position to date.
Jan 15, 2026, 8:00 PM
INVO Fertility discusses business strategy and market outlook
INVO
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- INVO is a specialty healthcare company in the fertility sector, operating three fully operational clinics and utilizing its FDA-cleared INVOcell device in its clinics and for third-party sales.
- The U.S. fertility market is estimated at $5-$7 billion annually, with high treatment costs and untreated patients being significant barriers, though recent government initiatives are expected to fuel demand.
- INVO's growth strategy includes organic efforts to increase patient flow and expand services at existing clinics, as well as a key near and intermediate-term focus on acquisitions, with a robust pipeline of opportunities.
- The company is actively re-emphasizing its INVOcell device sales through improved pricing and enhanced support, and recently announced the signing of a purchase agreement to acquire a practice in Indianapolis.
- The primary challenge and opportunity for 2026 is navigating the complexities of closing acquisitions despite an exceptional deal flow, with the company aiming for significant growth this year.
Jan 15, 2026, 8:00 PM
INVO Outlines 2026 Growth Strategy and Market Outlook
INVO
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- INVO is a specialty healthcare company in the fertility sector, operating three fully operational clinics and utilizing its FDA-cleared INVOcell device in its clinics and for sale to third parties.
- The U.S. fertility market is estimated at $5-$7 billion annually, experiencing steady growth, with recent policy updates expected to further accelerate demand by improving affordability.
- The company's growth strategy for 2026 focuses on both organic expansion, including increasing patient flow and service offerings, and acquisitions, with a robust pipeline of potential opportunities and the imminent completion of the Indianapolis acquisition.
- INVO is re-emphasizing its INVOcell device by improving pricing and enhancing training and support to drive awareness and utilization in 2025 and 2026.
- The company anticipates exciting growth in 2026, aiming to exit the year in its strongest position ever through a combination of organic efforts and acquisitions.
Jan 15, 2026, 8:00 PM
Quarterly earnings call transcripts for INVO.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more